Recent Finacing
Recent Raise
Cantargia develops monoclonal antibody therapeutics targeting IL1RAP on leukemic stem cells (CML/AML/ALL), advancing lead candidate through preclinical safety, GMP manufacturing preparation and partnership-driven commercialization.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors